From the Department of Neurology, Vanderbilt University Medical Center, Nashville, TN (E.A.M.).
Cincinnati Children's Hospital Medical Center, OH (H.S.).
Stroke. 2019 Dec;50(12):3449-3455. doi: 10.1161/STROKEAHA.119.026889. Epub 2019 Oct 7.
Background and Purpose- To identify the specific post-endovascular stroke therapy (EVT) peak systolic blood pressure (SBP) threshold that best discriminates good from bad functional outcomes (a priori hypothesized to be 160 mm Hg), we conducted a prospective, multicenter, cohort study with a prespecified analysis plan. Methods- Consecutive adult patients treated with EVT for an anterior ischemic stroke were enrolled from November 2017 to July 2018 at 12 comprehensive stroke centers accross the United States. All SBP values within 24 hours post-EVT were recorded. Using Youden index, the threshold of peak SBP that best discriminated primary outcome of dichotomized 90-day modified Rankin Scale score (0-2 versus 3-6) was identified. Association of this SBP threshold with the outcomes was quantified using multiple logistic regression. Results- Among 485 enrolled patients (median age, 69 [interquartile range, 57-79] years; 51% females), a peak SBP of 158 mm Hg was associated with the largest difference in the dichotomous modified Rankin Scale score (absolute risk reduction of 19%). Having a peak SBP >158 mm Hg resulted in an increased likelihood of modified Rankin Scale score 3 to 6 (odds ratio, 2.24 [1.52-3.29], <0.01; adjusted odds ratio, 1.29 [0.81-2.06], =0.28, after adjustment for prespecified variables). Conclusions- A peak post-EVT SBP of 158 mm Hg was prospectively identified to best discriminate good from bad functional outcome. Those with a peak SBP >158 had an increased likelihood of having a bad outcome in unadjusted, but not in adjusted analysis. The observed effect size was similar to prior studies. This finding should undergo further testing in a future randomized trial of goal-targeted post-EVT antihypertensive treatment.
背景与目的-为了确定最佳区分良好和不良功能结局的特定血管内治疗后收缩压峰值(SBP)阈值(假设为 160mmHg),我们进行了一项前瞻性、多中心、队列研究,并制定了预设的分析计划。方法-2017 年 11 月至 2018 年 7 月,在美国 12 个综合性卒中中心连续纳入接受血管内治疗的急性缺血性卒中成年患者。记录血管内治疗后 24 小时内的所有 SBP 值。使用约登指数,确定最佳区分 90 天改良 Rankin 量表评分(0-2 与 3-6)二分位数的峰值 SBP 阈值。使用多变量逻辑回归量化该 SBP 阈值与结局的关系。结果-在纳入的 485 例患者中(中位年龄,69[四分位距,57-79]岁;51%为女性),SBP 峰值为 158mmHg 与改良 Rankin 量表评分的差异最大(绝对风险降低 19%)。SBP 峰值>158mmHg 会增加改良 Rankin 量表评分 3-6 的可能性(比值比,2.24[1.52-3.29],<0.01;调整比值比,1.29[0.81-2.06],=0.28,在调整了预设变量后)。结论-前瞻性确定血管内治疗后 SBP 峰值 158mmHg 可最佳区分良好和不良功能结局。未经调整,SBP 峰值>158mmHg 的患者发生不良结局的可能性增加,但在调整后分析中并非如此。观察到的效应大小与既往研究相似。这一发现应在未来的血管内治疗后目标导向降压治疗的随机试验中进一步验证。